Literature DB >> 11337388

Bcl-2 expression in anaplastic large cell lymphoma.

C Villalva, F Bougrine, G Delsol, P Brousset.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11337388      PMCID： PMC1891935          DOI： 10.1016/S0002-9440(10)64146-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


× No keyword cloud information.
  7 in total

Review 1.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Anaplastic large cell lymphoma: a distinct molecular pathologic entity: a reappraisal with special reference to p80(NPM/ALK) expression.

Authors:  S Nakamura; M Shiota; A Nakagawa; Y Yatabe; M Kojima; T Motoori; R Suzuki; Y Kagami; M Ogura; Y Morishima; Y Mizoguchi; M Okamoto; M Seto; T Koshikawa; S Mori; T Suchi
Journal:  Am J Surg Pathol       Date:  1997-12       Impact factor: 6.394

Review 3.  ALK-positive lymphoma: a single disease with a broad spectrum of morphology.

Authors:  D Benharroch; Z Meguerian-Bedoyan; L Lamant; C Amin; L Brugières; M J Terrier-Lacombe; E Haralambieva; K Pulford; S Pileri; S W Morris; D Y Mason; G Delsol
Journal:  Blood       Date:  1998-03-15       Impact factor: 22.113

4.  Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway.

Authors:  R Y Bai; T Ouyang; C Miething; S W Morris; C Peschel; J Duyster
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

5.  Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily.

Authors:  M Paulli; E Berti; E Boveri; S Kindl; E Bonoldi; C Gambini; R Rosso; G Borroni; V Straccapansa; U Magrini; J E DeCoteau; P H Krammer; P Möller; M E Kadin
Journal:  Hum Pathol       Date:  1998-11       Impact factor: 3.466

6.  Immunodetection of apoptosis-regulating proteins in lymphomas from patients with and without human immunodeficiency virus infection.

Authors:  D Schlaifer; S Krajewski; S Galoin; F Rigal-Huguet; G Laurent; P Massip; J Pris; G Delsol; J C Reed; P Brousset
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

Review 7.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113
  7 in total
  4 in total

1.  High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma.

Authors:  R Rust; G Harms; T Blokzijl; M Boot; A Diepstra; J Kluiver; L Visser; S-C Peh; M Lim; W A Kamps; S Poppema; A van den Berg
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

Review 2.  A successfully treated inflammatory myofibroblastic tumor of the mandible with long-term follow-up and review of the literature.

Authors:  Takafumi Satomi; Masato Watanabe; Jun Matsubayashi; Toshitaka Nagao; Hiroshige Chiba
Journal:  Med Mol Morphol       Date:  2010-09-21       Impact factor: 2.309

3.  Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.

Authors:  Avedis Torossian; Nicolas Broin; Julie Frentzel; Camille Daugrois; Sarah Gandarillas; Talal Al Saati; Laurence Lamant; Pierre Brousset; Sylvie Giuriato; Estelle Espinos
Journal:  Haematologica       Date:  2019-01-24       Impact factor: 9.941

Review 4.  The Dual Role of Autophagy in Crizotinib-Treated ALK+ ALCL: From the Lymphoma Cells Drug Resistance to Their Demise.

Authors:  Estelle Espinos; Raymond Lai; Sylvie Giuriato
Journal:  Cells       Date:  2021-09-23       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.